Skip to main content
Premium Trial:

Request an Annual Quote

Shield Diagnostics: David Esposito

David Esposito has been appointed to the board of directors of Shield Diagnostics, a San Jose, California-based rapid molecular diagnostics firm developing assays for resistance-guided therapy. Esposito is currently CEO of ONL Therapeutics. He formerly served as CEO of Armune BioScience, a company that was sold to Exact Sciences in 2017, and he also served as President of Phadia US, an allergy and autoimmune diagnostics firm, playing a pivotal role in selling the business to Thermo Fisher Scientific in 2011.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.